ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS

ACTG 5178：丙型肝炎病毒的抑制性长期抗病毒治疗

• 批准号: 7605393
• 负责人: WILLIAM AUSTIN O'BRIEN
• 金额: $ 0.13万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605393
• 关键词: Antiviral Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; Hepatitis; Hepatitis C; Hepatitis C virus; Institution; Interferons; Liver; Participant; Procedures; Purpose; Rate; Research; Research Personnel; Resources; Ribavirin; Source; United States National Institutes of Health; Virus; Week; liver biopsy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: The purpose of this study is to find out whether long-term treatment with pegylated-interferon (PEG-IFN) slows the rate of liver damage caused by hepatitis C in people also infected with HIV. Specific Aims and Procedures (summary): Part 1: Participants will be given PEG-IFN and ribavirin for 12 weeks if they have never been treated for HCV; they have been treated in the past with PEG-IFN, IFN or IFN and ribavirin for up to one year, but have been off treatment for 12 weeks; or they have been treated with some form of IFN for at least 12 weeks and still have HCV. After 12 weeks of treatment, all participants will have a liver biopsy. Part 2: Participants who do not show signs of responding to the 12 weeks of treatment will be assigned by chance to either receive PEG-IFN alone for 72 weeks or to continue on study off treatment for 72 weeks. Part 3: Participants who sign signs of responding to the 12 weeks of treatment will continue to receive PEG-IFN and ribavirin for 72 weeks and then be followed on study for an additional 24 weeks off treatment. Significance (summary): Study findings will be available to participants.

这个子项目是众多研究子项目之一